Significant liver histological change is common in HBeAg-positive chronic hepatitis B with normal ALT.
Humans
Hepatitis B, Chronic
/ pathology
Male
Female
Adult
Hepatitis B e Antigens
/ blood
Retrospective Studies
Liver
/ pathology
Alanine Transaminase
/ blood
Middle Aged
Liver Cirrhosis
/ pathology
Hepatitis B virus
DNA, Viral
/ blood
Biopsy
Liver Neoplasms
/ pathology
Carcinoma, Hepatocellular
/ pathology
ALT, normal
Chronic hepatitis B
HBV DNA
Immune tolerance
Liver histology
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
23 Jul 2024
23 Jul 2024
Historique:
received:
31
08
2023
accepted:
15
07
2024
medline:
24
7
2024
pubmed:
24
7
2024
entrez:
23
7
2024
Statut:
epublish
Résumé
Numerous HBeAg-positive chronic hepatitis B (CHB) patients with persistently normal ALT have significant liver histopathology. It is imperative to identify true "immune tolerant" patients. We aimed to evaluate the liver histopathology features of HBeAg-positive CHB patients with normal ALT and the incidence of liver cirrhosis and HCC in CHB patients during follow-up. 179 HBeAg-positive CHB patients with normal ALT who performed liver biopsy from 2009 to 2018 were retrospectively analyzed. Liver necroinflammation ≥ G2 and/or liver fibrosis ≥ S2 was defined as significant liver histopathological change. 57.5% patients were in the indeterminate phase with significant liver histological changes. The proportion of the patients with evident liver necroinflammation was higher in the high-normal ALT group (21-40U/L) when compared with the low-normal ALT group (≤ 20 U/L) (51.3% vs. 30.0%, p < 0.05), and patients aged ≥ 40 years had a higher proportion of significant fibrosis than those aged < 40 years (64.5% vs. 39.9%, p < 0.05). The percentages of patients with ≥ S2 and ≥ G2/S2 in the HBV DNA < 10 HBeAg-positive CHB patients with high-normal ALT or HBV DNA < 10
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Numerous HBeAg-positive chronic hepatitis B (CHB) patients with persistently normal ALT have significant liver histopathology. It is imperative to identify true "immune tolerant" patients. We aimed to evaluate the liver histopathology features of HBeAg-positive CHB patients with normal ALT and the incidence of liver cirrhosis and HCC in CHB patients during follow-up.
METHODS
METHODS
179 HBeAg-positive CHB patients with normal ALT who performed liver biopsy from 2009 to 2018 were retrospectively analyzed. Liver necroinflammation ≥ G2 and/or liver fibrosis ≥ S2 was defined as significant liver histopathological change.
RESULTS
RESULTS
57.5% patients were in the indeterminate phase with significant liver histological changes. The proportion of the patients with evident liver necroinflammation was higher in the high-normal ALT group (21-40U/L) when compared with the low-normal ALT group (≤ 20 U/L) (51.3% vs. 30.0%, p < 0.05), and patients aged ≥ 40 years had a higher proportion of significant fibrosis than those aged < 40 years (64.5% vs. 39.9%, p < 0.05). The percentages of patients with ≥ S2 and ≥ G2/S2 in the HBV DNA < 10
CONCLUSIONS
CONCLUSIONS
HBeAg-positive CHB patients with high-normal ALT or HBV DNA < 10
Identifiants
pubmed: 39044129
doi: 10.1186/s12879-024-09617-1
pii: 10.1186/s12879-024-09617-1
doi:
Substances chimiques
Hepatitis B e Antigens
0
Alanine Transaminase
EC 2.6.1.2
DNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
723Informations de copyright
© 2024. The Author(s).
Références
Global prevalence. Treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403.
doi: 10.1016/S2468-1253(18)30056-6
Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009;29(Suppl 1):100–7.
doi: 10.1111/j.1478-3231.2008.01941.x
pubmed: 19207972
Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99.
doi: 10.1002/hep.29800
pubmed: 29405329
EASL. 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67(2): 370 – 98.
Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98.
doi: 10.1007/s12072-015-9675-4
pubmed: 26563120
Kao JH, Hu TH, Jia J, Kurosaki M, Lim YS, Lin HC, et al. East Asia expert opinion on treatment initiation for chronic hepatitis B. Aliment Pharmacol Ther. 2020;52(10):1540–50.
doi: 10.1111/apt.16097
pubmed: 32951256
Sarri G, Westby M, Bermingham S, Hill-Cawthorne G, Thomas H, et al. Diagnosis and management of chronic hepatitis B in children, young people, and adults: summary of NICE guidance. BMJ. 2013;26(346):f3893.
doi: 10.1136/bmj.f3893
Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6(12):1315–41.
doi: 10.1016/j.cgh.2008.08.021
pubmed: 18845489
Kumar M, Sarin SK, Hissar S, Jacobson IM, Martin P, Schiff ER, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology. 2008;134(5):1376–84.
doi: 10.1053/j.gastro.2008.02.075
pubmed: 18471514
Mason WS, Gill US, Litwin S, Zhou Y, Peri S, Pop O et al. HBV DNA integration and clonal hepatocyte expansion in Chronic Hepatitis B patients considered Immune Tolerant. Gastroenterology 2016; 151(5): 986 – 98. e4.
Bertoletti A, Ferrari C. Adaptive immunity in HBV infection. J Hepatol. 2016;64(1 Suppl):S71–83.
doi: 10.1016/j.jhep.2016.01.026
pubmed: 27084039
Kennedy PTF, Sandalova E, Jo J, Gill U, Ushiro-Lumb I, Tan AT, et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology. 2012;143(3):637–45.
doi: 10.1053/j.gastro.2012.06.009
pubmed: 22710188
Andreani T, Serfaty L, Mohand D, Dernaika S, Wendum D, Chazouillères O, et al. Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome. Clin Gastroenterol Hepatol. 2007;5(5):636–41.
doi: 10.1016/j.cgh.2007.01.005
pubmed: 17428739
Hui CK, Leung N, Yuen ST, Zhang HY, Leung KW, Lu L, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology. 2007;46(2):395–401.
doi: 10.1002/hep.21724
pubmed: 17628874
Nguyen MH, Garcia RT, Trinh HN, Lam KD, Weiss G, Nguyen HA, et al. Histological disease in asian-americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels. Am J Gastroenterol. 2009;104(9):2206–13.
doi: 10.1038/ajg.2009.248
pubmed: 19491836
Park JY, Park YN, Kim DY, Paik YH, Lee KS, Moon BS, et al. High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels. J Viral Hepat. 2008;15(8):615–21.
doi: 10.1111/j.1365-2893.2008.00989.x
pubmed: 18573162
Liao B, Wang Z, Lin S, Xu Y, Yi J, Xu M, et al. Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent normal ALT. PLoS ONE. 2013;8(10):e78672.
doi: 10.1371/journal.pone.0078672
pubmed: 24205292
pmcid: 3808379
Gui HL, Wang H, Yang YH, Wu YW, Zhou HJ, Guo SM, et al. Significant histopathology in Chinese chronic hepatitis B patients with persistently high-normal alanine aminotransferase. J Viral Hepat. 2010;17(Suppl 1):44–50.
doi: 10.1111/j.1365-2893.2010.01270.x
pubmed: 20586933
Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 2007;47(6):760–7.
doi: 10.1016/j.jhep.2007.07.022
pubmed: 17928090
Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. Clin Gastroenterol Hepatol. 2009;7(2):227–33.
doi: 10.1016/j.cgh.2008.10.023
pubmed: 19121647
Göbel T, Erhardt A, Herwig M, Poremba C, Baldus SE, Sagir A, et al. High prevalence of significant liver fibrosis and cirrhosis in chronic hepatitis B patients with normal ALT in central Europe. J Med Virol. 2011;83(6):968–73.
doi: 10.1002/jmv.22048
pubmed: 21503908
Wang Y, Xu MY, Zheng RD, Xian JC, Xu HT, Shi JP, et al. Prediction of significant fibrosis and cirrhosis in hepatitis B e-antigen negative patients with chronic hepatitis B using routine parameters. Hepatol Res. 2013;43(5):441–51.
doi: 10.1111/j.1872-034X.2012.01094.x
pubmed: 23006433
Duan M, Chi X, Xiao H, Liu X, Zhuang H, et al. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B. Hepatol Int. 2021;15(2):318–27.
doi: 10.1007/s12072-021-10153-2
pubmed: 33638049
Bai H, Liu H, Chen X, Xu C, Dou X. Influence of age and HBeAg status on the correlation between HBV DNA and hepatic inflammation and fibrosis in chronic hepatitis B patients. Dig Dis Sci. 2013;58(5):1355–62.
doi: 10.1007/s10620-012-2479-7
pubmed: 23179154
Xie Q, Hu X, Zhang Y, Jiang X, Li X, Li J. Decreasing hepatitis B viral load is associated with a risk of significant liver fibrosis in hepatitis B e antigen positive chronic hepatitis B. J Med Virol. 2014;86(11):1828–37.
doi: 10.1002/jmv.24000
pubmed: 25145769
Chen CF, Lee WC, Yang HI, Chang HC, Jen CL, Iloeje UH, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology. 2011;141(4):1240–8.
doi: 10.1053/j.gastro.2011.06.036
pubmed: 21703214
Lee HA, Lee HW, Kim IH, Park SY, Sinn DH, Yu JH, et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. Alimenta Pharmacol Ther. 2020;52(1):196–204.
doi: 10.1111/apt.15741
Kim HL, Kim GA, Park JA, Kang HR, Lee EK, Lim YS. Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B. Gut. 2021;70(11):2172–82.
doi: 10.1136/gutjnl-2020-321309
pubmed: 33239344
Jeng WJ, Lok AS. Should treatment indications for chronic Hepatitis B be expanded? [J]. Clin Gastroenterol Hepatol. 2021;19(10):2006–14.
doi: 10.1016/j.cgh.2020.04.091
pubmed: 32434068
Yoo JJ, Park SY, Moon JE, Lee YR, Lee HA, Lee J, et al. Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase. Clin Mol Hepatol. 2023;29(2):482–95.
doi: 10.3350/cmh.2022.0322
pubmed: 36603573
pmcid: 10121308
Wang J, Yan X, Zhu L, Liu J, Qiu Y, Li Y, et al. Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone. Aliment Pharmacol Ther. 2023;57(5):464–74.
doi: 10.1111/apt.17272
pubmed: 36324235
Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. [Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)]. Zhonghua Gan Zang Bing Za Zhi. 2022;30(12):1309–31.